ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1096

Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia

Shay Brikman1, Liel Serfaty, MA2, Ran Abuhasira, MD, PhD3, Naomi Schlesinger4, Nadav Rappoport5 and Amir Bieber6, 1Emek Medical Center, Afula, Israel, 2Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, 3Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, 4University of Utah, Salt Lake City, UT, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6Emek Medical Center, Clalit Health Services, Raanana, Israel

Meeting: ACR Convergence 2024

Keywords: gout, hyperuricemia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling with multiple variables may shed light on this phenomenon. The purpose of this study is to explore a multi factorial prediction model for gout of hyperuricemic people.

Methods: Data was extracted from Clalit Health Services national database. We included adults with at least two serum uric acid measurements of more than 6.8 mg/dL Patients with prior gout diagnoses or serum urate lowering medications were excluded. The primary outcome was gout diagnosis according to ICD-9 diagnosis recorded. A machine learning model, specifically XGBoost, was developed to predict gout development. Feature selection methods were used to identify relevant variables. The model’s performance was evaluated using receiver operating characteristic area under the curve (ROC AUC) and precision-recall AUC. Patients’ demographic characteristics, laboratory results, and medication records were used to train a risk prediction model. The model was split to train and test at a ratio of 80%-20% and evaluated using 5-cross validation. Feature selection methods were used to identify relevant variables.

Results: 301,385 individuals were defined as hyperuricemic of which 15,055 (5%) were diagnosed with gout.  A 125 variable model was created using XGBoost model which demonstrated strong performance with a ROC-AUC score of 0.781 (95% CI 0.78-0.784, Figure 2A) and a precision-recall- AUC of 0.208 (95% CI 0.195-0.22, Figure 2B). NPV was 97.8%. Of the 125 features incorporated in the model, 7 were demographic, 10 were laboratory results of which 5 regraded serum uric acid, 22 were comorbidities and 86 were drugs. Interestingly, some of the features and not globally generalizable such as specific district location, and ethnicity. Altogether five different ways to measure SUA were used including first and second mean, maximum, minimum, median and last before outcome. When taking two of the 125 features: age and second mean SUA, we were able to see that 23.25% of patients less than 50 years old with SUA between 9 and 12 mg/dl developed gout, which is by itself a high incidence rate. Age by itself revealed a non-linear fashion of gout risk, considering age and BMI yielded a relation demonstrating a pick in the 6th decade of life of both BMI and gout incidence, and lower incidence of gout among elderly (age >80) with lower BMI.

Using this machine learning modeling for prediction gout yielded multiple variables which may lead to the investigation of multiple associations affecting progression to gout.  

Conclusion: Using this machine learning modeling for prediction gout yielded multiple variables which may lead to the investigation of multiple associations affecting progression to gout.  

Supporting image 1

Gout probablility by age and average BMI

Supporting image 2

Number of patients with gout according to age and SU levels


Disclosures: S. Brikman: AbbVie/Abbott, 1, Pfizer, 12, Support for registering ACR/EULAR meeting; L. Serfaty, MA: None; R. Abuhasira, MD, PhD: None; N. Schlesinger: arthrosi, 1, horizon, 1, Novartis, 1, olatec, 1, 2, ptotalix, 1, 2, shanton, 1, sobi, 1; N. Rappoport: None; A. Bieber: AbbVie/Abbott, 1, AstraZeneca, 1, Eli Lilly, 1, Novartis, 1.

To cite this abstract in AMA style:

Brikman S, Serfaty, MA L, Abuhasira, MD, PhD R, Schlesinger N, Rappoport N, Bieber A. Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/exploring-multi-factorial-model-for-the-prediction-of-gout-in-patients-with-hyperuricemia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-multi-factorial-model-for-the-prediction-of-gout-in-patients-with-hyperuricemia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology